Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A (600613) - Total Assets
Based on the latest financial reports, Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A (600613) holds total assets worth CN¥3.09 Billion CNY (≈ $451.61 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Shanghai Shenqi Pharmaceutical Investmen for net asset value and shareholders' equity analysis.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A - Total Assets Trend (1992–2024)
This chart illustrates how Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's total assets have evolved over time, based on quarterly financial data.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's total assets of CN¥3.09 Billion consist of 51.2% current assets and 48.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 25.0% |
| Accounts Receivable | CN¥534.42 Million | 17.2% |
| Inventory | CN¥228.34 Million | 7.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥96.65 Million | 3.1% |
| Goodwill | CN¥243.85 Million | 7.8% |
Asset Composition Trend (1992–2024)
This chart illustrates how Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 600613 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's current assets represent 51.2% of total assets in 2024, a decrease from 69.3% in 1992.
- Cash Position: Cash and equivalents constituted 25.0% of total assets in 2024, down from 28.7% in 1992.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 1992.
- Asset Diversification: The largest asset category is accounts receivable at 17.2% of total assets.
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A Competitors by Total Assets
Key competitors of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
MX:NVSN
|
Mexico | MX$110.95 Billion |
|
Novo Nordisk A/S
CO:NOVO-B
|
Denmark | Dkr542.90 Billion |
|
Novartis AG
SW:NOVN
|
Switzerland | CHF115.49 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$208.73 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$1.83 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$112.48 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.83 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥17.48 Billion |
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.98 | 2.85 | 3.13 |
| Quick Ratio | 2.57 | 2.46 | 2.68 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.06 Billion | CN¥1.11 Billion | CN¥973.89 Million |
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A - Advanced Valuation Insights
This section examines the relationship between Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.46 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -5.0% |
| Total Assets | CN¥3.12 Billion |
| Market Capitalization | $408.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A's assets decreased by 5.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A (1992–2024)
The table below shows the annual total assets of Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A from 1992 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.12 Billion ≈ $455.94 Million |
-4.99% |
| 2023-12-31 | CN¥3.28 Billion ≈ $479.87 Million |
-3.01% |
| 2022-12-31 | CN¥3.38 Billion ≈ $494.76 Million |
+7.37% |
| 2021-12-31 | CN¥3.15 Billion ≈ $460.79 Million |
+1.65% |
| 2020-12-31 | CN¥3.10 Billion ≈ $453.33 Million |
-12.88% |
| 2019-12-31 | CN¥3.56 Billion ≈ $520.37 Million |
+13.74% |
| 2018-12-31 | CN¥3.13 Billion ≈ $457.50 Million |
+0.99% |
| 2017-12-31 | CN¥3.10 Billion ≈ $453.02 Million |
+3.11% |
| 2016-12-31 | CN¥3.00 Billion ≈ $439.36 Million |
+12.42% |
| 2015-12-31 | CN¥2.67 Billion ≈ $390.82 Million |
+18.51% |
| 2014-12-31 | CN¥2.25 Billion ≈ $329.77 Million |
+12.94% |
| 2013-12-31 | CN¥2.00 Billion ≈ $291.99 Million |
+695.26% |
| 2012-12-31 | CN¥250.92 Million ≈ $36.72 Million |
+3.23% |
| 2011-12-31 | CN¥243.07 Million ≈ $35.57 Million |
+10.06% |
| 2010-12-31 | CN¥220.85 Million ≈ $32.32 Million |
-9.51% |
| 2009-12-31 | CN¥244.05 Million ≈ $35.71 Million |
-6.81% |
| 2008-12-31 | CN¥261.87 Million ≈ $38.32 Million |
-11.09% |
| 2007-12-31 | CN¥294.52 Million ≈ $43.10 Million |
+0.28% |
| 2006-12-31 | CN¥293.68 Million ≈ $42.97 Million |
-0.31% |
| 2005-12-31 | CN¥294.59 Million ≈ $43.11 Million |
-18.44% |
| 2004-12-31 | CN¥361.19 Million ≈ $52.85 Million |
+24.47% |
| 2003-12-31 | CN¥290.19 Million ≈ $42.46 Million |
+0.23% |
| 2002-12-31 | CN¥289.51 Million ≈ $42.37 Million |
-29.21% |
| 2001-12-31 | CN¥408.99 Million ≈ $59.85 Million |
-22.85% |
| 2000-12-31 | CN¥530.13 Million ≈ $77.57 Million |
+9.04% |
| 1999-12-31 | CN¥486.20 Million ≈ $71.15 Million |
-34.96% |
| 1998-12-31 | CN¥747.54 Million ≈ $109.39 Million |
+29.73% |
| 1997-12-31 | CN¥576.22 Million ≈ $84.32 Million |
+11.15% |
| 1996-12-31 | CN¥518.43 Million ≈ $75.86 Million |
+5.99% |
| 1995-12-31 | CN¥489.14 Million ≈ $71.58 Million |
+0.70% |
| 1994-12-31 | CN¥485.73 Million ≈ $71.08 Million |
+15.48% |
| 1993-12-31 | CN¥420.63 Million ≈ $61.55 Million |
+15.25% |
| 1992-12-31 | CN¥364.96 Million ≈ $53.41 Million |
-- |
About Shanghai Shenqi Pharmaceutical Investment Management Co Ltd A
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, tonic and sedative, cold and cough, anti-fungal, gynecology, and other treatment fiel… Read more